MTOR and neoplasm: CB‐839, a GLS inhibitor, enhances the tumoricidal activity of natural killer cells by blocking glutamine used by tumor cells, boosting glutamine availability in the TME, and activating the mTOR and c‐Myc signaling pathways [187].